Gender-affirming hormone therapy
GAHT · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Hormonal treatment to align secondary sexual characteristics with gender identity in transgender and gender-diverse adults, using oestrogen (with antiandrogen) or testosterone. Requires informed consent, baseline risk assessment and ongoing monitoring.
Red flags
- Symptoms/signs of venous thromboembolism (oestrogen)
- Haematocrit above threshold (testosterone-induced polycythaemia)
- New severe headache/visual change (prolactinoma on oestrogen)
- Marked transaminase rise
- Uncontrolled cardiovascular disease
Assessment
Differential diagnosis
- Other causes of gender dysphoria mimics
- Endocrine conditions needing exclusion before therapy (e.g. prolactinoma)
- Secondary causes of hypogonadism
Investigations
- Baseline hormone profile (testosterone, oestradiol, LH/FSH)
- Metabolic screen: lipids, glucose/HbA1c, liver and renal function
- Full blood count (haematocrit for testosterone)
- Prolactin (before/during oestrogen)
- VTE and cardiovascular risk assessment; bone density if long-term hypogonadism
Management
- Confirm informed consent and assess cardiovascular, thrombotic and cancer risk
- Address modifiable risks (smoking cessation particularly before oestrogen)
- For feminising therapy, start oestradiol and add an antiandrogen to suppress testosterone
- For masculinising therapy, start testosterone and titrate to male physiological range
- Set realistic timelines for reversible and irreversible changes and discuss fertility preservation
- Monitor hormone levels and titrate to target ranges
- Screen for polycythaemia (testosterone) and VTE/prolactin (oestrogen)
- Continue age/anatomy-appropriate cancer screening
- Review bone health with prolonged therapy
- Coordinate with any planned surgical care and adjust therapy accordingly
Drugs & doses
Estradiol valerate 2-6 mg PO daily or transdermal estradiol patch/gel titrated
Antiandrogen: spironolactone 100-200 mg PO daily or cyproterone acetate low dose (or GnRH analogue)
Testosterone gel daily or testosterone undecanoate IM 1000 mg every 10-14 weeks
GnRH analogue (e.g. leuprorelin/goserelin) for gonadal suppression where used
Disposition
Provide through gender/endocrine services with informed consent and shared monitoring; refer for fertility counselling and surgical pathways as desired.
Complications & pitfalls
- Venous thromboembolism (oestrogen, worse with smoking/oral route)
- Polycythaemia (testosterone)
- Hyperprolactinaemia
- Dyslipidaemia/cardiovascular risk changes
- Reduced fertility/bone loss if gonadal suppression without adequate replacement
Exam pearls
- Transdermal oestrogen lowers VTE risk compared with oral, especially in smokers and older patients
- Discuss and offer fertility preservation before starting therapy, as some effects are irreversible
- Monitor haematocrit on testosterone and prolactin on oestrogen
- Maintain anatomy-appropriate cancer screening regardless of gender identity
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.